The utility of whole exome sequencing for genetic diagnosis in familial epilepsy
Închide
Articolul precedent
Articolul urmator
453 3
Ultima descărcare din IBN:
2021-12-22 08:00
Căutarea după subiecte
similare conform CZU
[575.1+577.352]:616.853 (1)
Genetică generală. Citogenetică generală (427)
Bazele materiale ale vieții. Biochimie. Biologie moleculară. Biofizică (664)
Neurologie. Neuropatologie. Sistem nervos (971)
SM ISO690:2012
GASNAȘ (CATERENIUC), Daniela, CHELBAN, Viorica, GROPPA, Stanislav. The utility of whole exome sequencing for genetic diagnosis in familial epilepsy. In: International Congress of Geneticists and Breeders from the Republic of Moldova, Ed. 11, 15-16 iunie 2021, Chişinău. Chișinău, Republica Moldova: Centrul Editorial-Poligrafic al Universităţii de Stat din Moldova, 2021, Ediția 11, p. 52. ISBN 978-9975-933-56-8. DOI: https://doi.org/10.53040/cga11.2021.034
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
International Congress of Geneticists and Breeders from the Republic of Moldova
Ediția 11, 2021
Congresul "International Congress of Geneticists and Breeders from the Republic of Moldova"
11, Chişinău, Moldova, 15-16 iunie 2021

The utility of whole exome sequencing for genetic diagnosis in familial epilepsy

DOI:https://doi.org/10.53040/cga11.2021.034
CZU: [575.1+577.352]:616.853

Pag. 52-52

Gasnaș (Catereniuc) Daniela12, Chelban Viorica13, Groppa Stanislav12
 
1 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
2 Emergency Institute of Medicine,
3 UCL Queen Square Institute of Neurology
 
 
Disponibil în IBN: 15 iunie 2021


Rezumat

Although several theories are implicated in the origin of epilepsy, its cause is still unknown in about 50% of cases. To associate a gene with epilepsy for the first time, families with multiple affected members are needed. The aim of our study is carrying out a clinical-genetic study of multiplex families from Republic of Moldova, for estimating the genetic biomarkers and establishing their weight in epileptogenesis, for further elaboration of a family risk prediction score. In order to achieve the set objective, an epidemiological, descriptive study (2018-2023) started with lancing a National Epilepsy Registry for multiplex families – families with at least 2 relatives of 1st degree with definite epilepsy of unknown aetiology, presumed genetic. The first 10 families were submitted to Whole Exome Sequencing (WES). Our National Epilepsy Registry consists now of 74 families including 186 members. We noted a negative trend of cases of epilepsy with advancing age and an overall prevalence of female subjects. The seizure onset, based on the available EEGs, was mostly focal, and the seizure type – mostly motor. The awareness during the seizures, in the majority of the affected subjects – was impaired. The first WES results showed that the most involved chromosomes in Moldovan probands, with potentially epileptogenic variants are the pairs 4, 7, 10, 12, 15 and 17. We also underlined the mostly affected genes: AUTS2, KCNMA1, SUFU, CHL1, MYH1, EDC3, LIAS, TBCD and ATXN1 genes. From all the detected variants, 24% were classified as deleterious and probably pathogenic, 45% were tolerated according to SIFT and 8% were benign or of unknown significance (VUS) according to Polyphen. The rest 22% were VUS according to both predictors. The familial segregation induced the “bottle neck” effect (the families’ cases remain unresolved), demonstrating the role of the trio sequencing in increasing the WES accuracy. Subjects continue to be recruited and included in the National Register of epilepsy of unknown aetiology, presumed genetic. The register is constantly being updated.